ABSTRACT

Objective:

Psoriatic arthritis (PsA) is one of the spondyloarthropathies associated with psoriasis. Recent data suggest an increased prevalence of cardiovascular disease in patients with PsA, similar to that observed in psoriasis. Fetuin-A is a novel biomarker related to vascular calcification and atherosclerosis. In this study, we aimed to investigate the association between fetuin-A concentrations and PsA-related parameters.

Methods:

Ninety-seven non-diabetic PsA patients who fulfilled the CASPAR criteria and 57 age- and sex-matched healthy controls were included. Disease activity was assessed by using CPDAI, BASDAI, DAS28-CRP and PASI. Serum lipids, high-sensitivity C-reactive protein (hs-CRP), erythrocyte sedimentation rate (ESR), and fetuin-A were studied.

Results:

There were 97 PsA patients [48 (min-max: 25-65) years, 32M/65F] and 57 healthy subjects [43 (min-max: 31-57) years, 24M/33F]. Disease duration of the PsA patients was 4 (min-max: 0-43) years. Distributions of age, sex, and body mass index were similar between the groups. Fetuin-A concentrations were significantly lower in the patients than in controls (p<0.001). When the PsA group was divided into peripheral (n=14), axial (n=52) and both peripheral and axial subgroups (n=31), fetuin A remained significantly lower in the each group compared to controls (p<0.001). There were negative correlations between fetuin-A concentrations and CPDAI, PASI, hs-CRP and ESR (r=-0.26, r=-0.25, r=-0.3, and r=-0.26, respectively; p<0.05).

Conclusion: Fetuin-A was lower in the PsA group than in healthy controls, regardless of disease subgroups. The negative relationship of this marker with acute phase reactants and disease activity indices suggests that reduced fetuin-A levels are associated with disease-related factors.

References

1Gupta S, Syrimi Z, Hughes DM, Zhao SS. Comorbidities in psoriatic arthritis: a systematic review and meta-analysis. Rheumatol Int 2021;41:275-84.

2Jirak P, Stechemesser L, Moré E, et al. Clinical implications of fetuin-A. Adv Clin Chem 2019;89:79-130.

3Clemente A, Traghella I, Mazzone A, Sbrana S, Vassalle C. Vascular and valvular calcification biomarkers. Adv Clin Chem 2020;95:73-103.

4Sari I, Kebapcilar L, Taylan A, et al. Fetuin-A and interleukin-18 levels in ankylosing spondylitis. Int J Rheum Dis 2010;13:75-81.

5Sari I, Yuksel A, Kozaci D, et al. The effect of regular colchicine treatment on biomarkers related with vascular injury in newly diagnosed patients with familial Mediterranean fever. Inflammation 2012;35:1191-7.

6Kawano M, Hirano T, Matsuda T, et al. Autocrine generation and requirement of BSF-2/IL-6 for human multiple myelomas. Nature 1988;332:83-5.

7Taylor W, Gladman D, Helliwell P, et al; CASPAR Study Group. Classification criteria for psoriatic arthritis: development of new criteria from a large international study. Arthritis Rheum 2006;54:2665-73.

8Wells G, Becker JC, Teng J, et al. Validation of the 28-joint Disease Activity Score (DAS28) and European League Against Rheumatism response criteria based on C-reactive protein against disease progression in patients with rheumatoid arthritis, and comparison with the DAS28 based on erythrocyte sedimentation rate. Ann Rheum Dis 2009;68:954-60.

9Garrett S, Jenkinson T, Kennedy LG, Whitelock H, Gaisford P, Calin A. A new approach to defining disease status in ankylosing spondylitis: the Bath Ankylosing Spondylitis Disease Activity Index. J Rheumatol 1994;21:2286-91.

10Leung YY, Orbai AM, de Wit M, et al; Remission/Flare in PsA Study Group. Comparing the patient-reported physical function outcome measures in a real-life ınternational cohort of patients with psoriatic arthritis. Arthritis Care Res (Hoboken) 2021;73:593-602.

11Calin A, Garrett S, Whitelock H, et al. A new approach to defining functional ability in ankylosing spondylitis: the development of the Bath Ankylosing Spondylitis Functional Index. J Rheumatol 1994;21:2281-5.

12Duruöz MT, Gezer HH, Nas K, et al. The impact of fatigue on patients with psoriatic arthritis: a multi-center study of the TLAR-network. Rheumatol Int 2020;40:1803-15.

13Sbidian E, Chaimani A, Afach S, et al. Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis. Cochrane Database Syst Rev 2020;1:CD011535. doi: 10.1002/14651858.CD011535.pub3. Update in: Cochrane Database Syst Rev 2021;4:CD011535.

14Farkas F, Ikumi N, Elmamoun M, Szentpetery A, FitzGerald O. Comparison of composite measure remission targets in psoriatic arthritis. J Rheumatol 2021:jrheum.200556. doi: 10.3899/jrheum.200556. Epub ahead of print.

15Hollan I, Meroni PL, Ahearn JM, et al. Cardiovascular disease in autoimmune rheumatic diseases. Autoimmun Rev 2013;12:1004-15.

16John H, Toms TE, Kitas GD. Rheumatoid arthritis: is it a coronary heart disease equivalent? Curr Opin Cardiol 2011;26:327-33.

17Papagoras C, Voulgari PV, Drosos AA. Atherosclerosis and cardiovascular disease in the spondyloarthritides, particularly ankylosing spondylitis and psoriatic arthritis. Clin Exp Rheumatol 2013;31:612-20.

18Horreau C, Pouplard C, Brenaut E, et al. Cardiovascular morbidity and mortality in psoriasis and psoriatic arthritis: a systematic literature review. J Eur Acad Dermatol Venereol 2013;27(Suppl 3):12-29.

19Poredos P. Intima-media thickness: indicator of cardiovascular risk and measure of the extent of atherosclerosis. Vasc Med 2004;9:46-54.

20Pober JS, Sessa WC. Evolving functions of endothelial cells in inflammation. Nat Rev Immunol 2007;7:803-15.

21Raitakari OT, Celermajer DS. Flow-mediated dilatation. Br J Clin Pharmacol 2000;50:397-404.

22Sari I, Kebapcilar L, Alacacioglu A, et al. Increased levels of asymmetric dimethylarginine (ADMA) in patients with ankylosing spondylitis. Intern Med 2009;48:1363-8.

23Fromm S, Cunningham CC, Dunne MR, Veale DJ, Fearon U, Wade SM. Enhanced angiogenic function in response to fibroblasts from psoriatic arthritis synovium compared to rheumatoid arthritis. Arthritis Res Ther 2019;21:297.

24Peluso R, Caso F, Tasso M, et al. Biomarkers of subclinical atherosclerosis in patients with psoriatic arthritis. Open Access Rheumatol Res Rev 2019;11:143-156.

25Mori K, Emoto M, Inaba M. Fetuin-A: a multifunctional protein. Recent Pat Endocr Metab Immune Drug Discov 2011;5:124-46.

26Zhou Z, Ji Y, Ju H, Chen H, Sun M. Circulating fetuin-a and risk of all-cause mortality in patients with chronic kidney disease: a systematic review and meta-analysis. Front Physiol 2019;10:966.

27Aroner SA, St-Jules DE, Mukamal KJ, et al. Fetuin-A, glycemic status, and risk of cardiovascular disease: The Multi-Ethnic Study of Atherosclerosis. Atherosclerosis 2016;248:224-9.

28Mori K, Emoto M, Inaba M. Fetuin-A and the cardiovascular system. Adv Clin Chem 2012;56:175-95.

29Weikert C, Stefan N, Schulze MB, et al. Plasma fetuin-a levels and the risk of myocardial ınfarction and ıschemic stroke. Circulation 2008;118:2555-62.

30Rittig K, Thamer C, Haupt A, et al. High plasma fetuin-a is associated with ıncreased carotid ıntima-media thickness in a middle-aged population. Atherosclerosis 2009;207:341-2.

31Gerdes S, Osadtschy S, Buhles N, Baurecht H, Mrowietz U. Cardiovascular biomarkers in patients with psoriasis. Exp Dermatol 2014;23:322-5.

32Sato H, Kazama JJ, Wada Y, et al. Decreased levels of circulating α2-heremans-schmid glycoprotein/fetuin-a (AHSG) in patients with rheumatoid arthritis. Intern Med 2007;46:1685-92.

33Ix JH, Shlipak MG, Brandenburg VM, Ali S, Ketteler M, Whooley MA. Association between human fetuin-A and the metabolic syndrome: data from the Heart and Soul Study. Circulation 2006;113:1760-7.

Fetuin-A and its association with disease activity in psoriatic arteritis

ABSTRACT

References